Estrone (E1): What This Test Actually Measures

What Estrone Is and Why It Exists as a Separate Lab Value

Estrone is a naturally occurring C18 steroid hormone produced primarily in the ovaries during reproductive years and in adipose tissue after menopause. The human body produces three classical estrogens: estradiol (E2), estrone (E1), and estriol (E3). Each binds estrogen receptors ERα and ERβ, but with different affinities. Estradiol binds ERα with roughly 10 to 12 times the potency of estrone, which is why estrone alone rarely produces the full tissue effects seen with normal premenopausal estradiol levels [1].

Measuring estrone as a distinct value matters because its relative contribution to total estrogenic activity shifts dramatically across the lifespan. During the reproductive years it is a minor player. After the final menstrual period, peripheral aromatization of adrenal androstenedione in fat cells becomes the dominant pathway for estrogen production, and estrone becomes the primary circulating estrogen [2].

The Three Estrogens and How They Relate

• Estradiol (E2): The most biologically active; dominant during reproductive years; produced mainly by ovarian granulosa cells.
• Estrone (E1): Weaker; interconverts with estradiol via 17β-hydroxysteroid dehydrogenase; becomes dominant postmenopause.
• Estriol (E3): Produced mainly by the placenta during pregnancy; the weakest of the three.

Estrone and estradiol interconvert bidirectionally. When a clinician sees an elevated estrone value in a postmenopausal patient who is not on hormone therapy, the first question is whether that estrone is converting to bioactive estradiol in tissue, which cannot be confirmed by serum E1 alone [3].

How the Lab Actually Measures E1

Most reference laboratories now use liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the preferred method because it avoids cross-reactivity artifacts seen with older immunoassay platforms, particularly at the low concentrations encountered in postmenopausal or male patients [4]. The Endocrine Society's 2019 position statement on sex steroid assays explicitly recommends LC-MS/MS over direct immunoassay for estrogens when clinical decisions hinge on low-range values [5].

A standard estrone panel requires a single serum draw. No fasting is needed, though a morning draw improves day-to-day reproducibility. Results are reported in picograms per milliliter (pg/mL) in the United States, or in picomoles per liter (pmol/L) in most European and Canadian laboratories (conversion: 1 pg/mL ≈ 3.7 pmol/L).

Normal Estrone (E1) Ranges Across Life Stages

Reference ranges vary by laboratory method, patient sex, and life stage. The values below reflect consensus from Endocrine Society guidelines and published LC-MS/MS validation studies [5, 6].

Women: Premenopausal

| Cycle Phase | Approximate E1 Range | |---|---| | Follicular | 17 to 200 pg/mL | | Midcycle (LH surge) | 100 to 400 pg/mL | | Luteal | 40 to 170 pg/mL |

Estrone rises in parallel with estradiol but at lower absolute values. During the midcycle surge, the ratio of E2 to E1 typically favors E2 by a factor of 3 to 5 [6].

Women: Postmenopausal

The Endocrine Society defines the expected postmenopausal estrone range (no exogenous hormone therapy) as 7 to 40 pg/mL [5]. Values above 40 pg/mL in a postmenopausal woman not on HRT warrant investigation for excess adipose aromatization, an estrogen-secreting ovarian tumor, or exogenous estrogen exposure.

Men

Adult men produce small amounts of estrone through peripheral aromatization of androstenedione. The typical adult male reference range is 10 to 60 pg/mL, with levels that rise progressively with increasing body mass index due to increased adipose aromatase activity [7].

Children and Adolescents

Prepubertal children have estrone values below 10 pg/mL. Detectable elevation before age 8 in girls or age 9 in boys may indicate precocious puberty and warrants pediatric endocrinology referral [8].

What a High Estrone Level Means

An estrone result above the age- and sex-specific reference range points toward one of four main categories: excess peripheral aromatization, exogenous estrogen exposure, an estrogen-secreting neoplasm, or laboratory artifact from immunoassay cross-reactivity.

Excess Peripheral Aromatization

Adipose tissue expresses aromatase (CYP19A1), the enzyme that converts androstenedione to estrone. In individuals with obesity, more aromatase surface area means more conversion. A cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism found that estrone concentrations correlated positively with body fat percentage (r = 0.61, P<0.001) in postmenopausal women independent of age [9].

This pathway explains why postmenopausal women with obesity carry higher baseline estrone levels, which in turn may sustain modest estrogenic stimulation of the endometrium. Epidemiological data from the Women's Health Initiative (N = 161,808 enrolled) showed that postmenopausal women with a BMI above 30 kg/m² had significantly higher circulating estrogen concentrations than normal-weight women, contributing to endometrial cancer risk even without exogenous hormone use [10].

Estrogen-Secreting Tumors

Granulosa cell tumors of the ovary and some adrenocortical carcinomas can secrete estrone directly. Unexplained postmenopausal bleeding combined with elevated estrone and a suppressed FSH (below 20 mIU/mL in a postmenopausal context) is a red-flag pattern that should prompt pelvic ultrasound and tumor marker testing [11].

Monitoring Oral Hormone Therapy

Oral estradiol undergoes first-pass hepatic metabolism, converting a significant fraction to estrone. After a 1 mg oral estradiol dose, serum estrone concentrations often exceed estradiol by a ratio of 3:1 or higher, a pharmacokinetic effect that does not occur with transdermal estradiol [12]. Clinicians tracking HRT adequacy in patients on oral regimens therefore need estrone results alongside estradiol to understand the full estrogenic load.

What a Low Estrone Level Means

Low estrone in a premenopausal woman suggests reduced ovarian output, which may reflect hypothalamic suppression, premature ovarian insufficiency (POI), or hyperprolactinemia. In a postmenopausal woman, a low-normal estrone is the expected finding and requires no intervention unless symptoms of estrogen deficiency are present.

Premature Ovarian Insufficiency

The American College of Obstetricians and Gynecologists (ACOG) defines POI as ovarian dysfunction before age 40, characterized by amenorrhea, FSH above 25 IU/L on two occasions at least four weeks apart, and low estrogen [13]. Estrone in this context may fall below 20 pg/mL alongside estradiol below 20 pg/mL. The Endocrine Society's 2015 clinical practice guideline on POI recommends initiating hormone therapy to reduce cardiovascular and bone density risks until at least the average age of natural menopause (approximately 51 years) [14].

Hypothalamic Amenorrhea

Energy-deficient states such as relative energy deficiency in sport (RED-S) suppress GnRH pulsatility, reducing LH and FSH and therefore both ovarian estradiol and estrone production. Estrone may fall below 17 pg/mL in athletes with functional hypothalamic amenorrhea. A 2021 review in the Journal of Clinical Endocrinology and Metabolism noted that bone mineral density loss in this population accelerates at estradiol values below 50 pg/mL, and since estrone is a partial proxy for total estrogenic exposure, serial monitoring of both hormones is warranted [15].

After Aromatase Inhibitor Therapy

Aromatase inhibitors (anastrozole, letrozole, exemestane) used in breast cancer treatment or in men with testosterone-related estrogen excess suppress peripheral estrone production by blocking CYP19A1. Estrone can fall to near-undetectable levels (<5 pg/mL) in women on therapeutic doses of letrozole 2.5 mg daily, producing symptoms of profound estrogen deficiency including bone loss, joint pain, and vasomotor symptoms [16].

How to Lower Estrone (E1)

Clinically significant estrone elevation is addressed by targeting its dominant source: excess aromatase activity in adipose tissue.

Reduce Adipose Aromatase Activity

Weight loss is the most evidence-based intervention. A randomized trial by Caan et al. Published in the Journal of Clinical Oncology (N = 2,361) found that a combined diet and exercise intervention producing 5 to 10% body weight reduction lowered serum estrone by a mean of 11.4% over 12 months in postmenopausal women [17].

Aromatase Inhibitor Therapy

When elevated estrone is driving endometrial hyperplasia or contributing to hormone-sensitive breast cancer risk, oncologists or gynecologists may use anastrozole 1 mg daily or letrozole 2.5 mg daily to suppress production. This is a prescription intervention with significant side effects and is not appropriate as a general wellness strategy [16].

Dietary Considerations

Cruciferous vegetables contain indole-3-carbinol (I3C), which converts in the gut to diindolylmethane (DIM). Some evidence from small pilot trials suggests DIM may shift estrogen metabolism toward less active 2-hydroxyestrone metabolites, though the data remain preliminary and no guideline body recommends DIM supplementation for estrone reduction at this time [18].

How to Raise Estrone (E1)

Low estrone in symptomatic patients is addressed through hormone therapy or by treating the underlying suppressive condition.

Hormone Therapy

The most direct method is exogenous estrogen replacement. Oral estradiol preferentially raises estrone due to hepatic first-pass conversion. A patient on 1 mg oral 17β-estradiol daily may achieve an estrone level of 100 to 150 pg/mL, approximately three times the estradiol concentration reached with that same dose [12].

Transdermal estradiol (patches, gels, or sprays) bypasses first-pass metabolism, producing a serum E2-to-E1 ratio closer to 1:1, which better replicates premenopausal physiology. The 2022 Menopause Society (formerly NAMS) position statement on hormone therapy notes that transdermal delivery avoids the supraphysiologic estrone elevations associated with oral administration and may carry a lower venous thromboembolism risk [19].

Treating the Underlying Cause

If low estrone reflects hypothalamic suppression from energy deficiency, the primary intervention is caloric rehabilitation and reduction of exercise load, not exogenous estrogen. If hyperprolactinemia is suppressing gonadotropins, cabergoline (0.25 to 1 mg twice weekly) can restore pulsatile GnRH output and allow natural estrone recovery [20].

Estrone vs. Estradiol: Which Test Should You Order?

The clinical decision between ordering estrone, estradiol, or both depends on the question being asked.

When to Order Estradiol Alone

Estradiol (E2) is the primary test for assessing ovarian function in premenopausal women, monitoring response to ovarian stimulation during assisted reproduction, and evaluating perimenopausal transition. It is the more biologically active hormone, and in reproductive-age patients it carries the most diagnostic weight [5].

When to Order Estrone

Order estrone when the patient is postmenopausal, because estrone is the dominant circulating estrogen in that population and estradiol may be so low as to fall below the assay's reliable detection threshold. Estrone is also the preferred measurement when investigating exogenous oral estrogen pharmacokinetics, evaluating a suspected estrogen-secreting tumor, or assessing the contribution of adipose aromatization to total estrogenic exposure.

When to Order Both

Both values together provide the E1-to-E2 ratio, which helps distinguish oral HRT pharmacokinetics from transdermal regimens and can identify tissue-level interconversion patterns that neither value reveals alone. The Endocrine Society recommends measuring both when clinical decisions depend on total estrogenic burden rather than a single hormone signal [5].

A clear decision structure for ordering:

| Clinical Question | Recommended Test | |---|---| | Ovarian reserve / cycle function | Estradiol (E2) | | Postmenopausal estrogen status | Estrone (E1) | | Oral HRT monitoring | Both E1 and E2 | | Transdermal HRT monitoring | Estradiol (E2) preferred | | Suspected estrogen-secreting tumor | Both E1 and E2 plus inhibin B | | Aromatase inhibitor monitoring | Estrone (E1) preferred |

Interpreting Estrone in Clinical Context

A single estrone value is rarely sufficient for a definitive clinical conclusion. The number must be interpreted alongside FSH, LH, estradiol, sex hormone-binding globulin (SHBG), and clinical symptoms.

The Role of SHBG

SHBG binds estrogens (and androgens), limiting their free bioavailable fraction. High SHBG, which can result from oral estrogen therapy or hyperthyroidism, may lower free estrone even when total estrone is elevated. This is why measuring total estrone alongside SHBG provides a more complete picture of bioavailable estrogenic activity [7].

FSH as a Counterpart

FSH above 25 to 40 IU/L in a woman under 40 alongside low estrone confirms POI. In a postmenopausal woman, FSH above 30 IU/L with estrone below 20 pg/mL is the expected pattern. A postmenopausal FSH that is paradoxically low (below 15 IU/L) alongside elevated estrone should prompt evaluation for an estrogen-secreting neoplasm or exogenous estrogen exposure [11].

Timing the Draw

In premenopausal women, estrone fluctuates across the menstrual cycle. Ordering the test without noting cycle day makes interpretation unreliable. The Endocrine Society recommends that cycle-dependent hormones be drawn on days 2 to 5 of the follicular phase for baseline assessment unless a specific cycle-phase question is being asked [5].

The Endocrine Society's 2015 clinical practice guidelines state: "For assessment of ovarian function and estrogen status, specimen timing relative to menstrual cycle phase must be documented; failure to do so renders estrogen measurements uninterpretable in women with intact ovarian function" [14].